Machinify (New Mountain Capital) acquires Performant Healthcare Inc for USD 7.75 (2025)

Deal facts

Buyer: Machinify (New Mountain Capital)
Target: Performant Healthcare Inc
Deal value: USD 7.75
Announced: 21 October 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

21 Oct 2025CompletedClosed
Machinify (New Mountain Capital) completes acquisition of Performant Healthcare Inc
INTRODUCTORY NOTE On October 21, 2025 (the “Closing Date”), Continental Buyer, Inc., a Delaware corporation (“Parent”), completed the previously announced acquisition of Performant Healthcare, Inc., a Delaware corporation (the “ Company”), pursuant to the Agreement and Plan of Merger, dated as of July 31, 2025 (the “Merger Agreement”), by and among the Company, Parent and Project Prevail Merger Su
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Performant Healthcare Inc by Parent, announced on 21 October 2025. This transaction, valued at 7.75 million USD, is a straightforward going-private deal settled entirely in cash. The move removes the target from public markets and places it under private ownership. For the SME founder watching this space, the structure offers a specific lesson in simplicity. There are no complex earn-outs, no contingent value rights, and no share-swap mechanics to complicate the exit. The buyer paid cash and took full control.

The sector context matters here. Healthcare assets often face intense regulatory scrutiny, particularly when competition concerns or anti-trust thresholds are triggered. In this instance, the deal has already completed, which implies that all necessary regulatory clearances were secured without material delay. This is a significant achievement in a sector where the CMA or equivalent bodies often demand deep dives into market concentration. The clean cash consideration suggests the buyer was confident in the asset quality and willing to absorb the full risk upfront. It also indicates that the target did not require the buyer to retain a portion of the purchase price in escrow to cover potential post-close liabilities, a common feature in healthcare transactions where compliance risks can linger.

We think this deal highlights the value of a clean exit path for private operators. The going-private route allows management to focus on long-term operational improvements without the quarterly pressure of public reporting. The cash nature of the consideration eliminates the currency risk that often plagues cross-border deals, even though both parties are based in the US. For the founder planning their own exit, the key is to ensure your financials are robust enough to support a cash-only bid. Buyers will not wait for regulatory hurdles to clear if the path is uncertain, so having your compliance house in order before you start the process is essential.

Your action item this week is to review your own regulatory compliance documentation and identify any potential change-of-control covenants in your current debt or lease agreements that could block a cash sale. Do not wait for a buyer to find these issues during due diligence.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from Machinify (New Mountain Capital)All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history